Australian Clinical Labs (ASX:ACL) Issuance of Debt: A$40.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ACL Australian Clinical Labs Ltd ASX:ACL
56 GF Score
Price A$2.38
GF Value A$3.06
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Australian Clinical Labs Issuance of Debt?

Australian Clinical Labs ASX:ACL -0.83% 56 Issuance of Debt is A$40.0 Mil as of Dec. 2025. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Australian Clinical Labs's Issuance of Debt for the six months ended in Dec. 2025 was A$35.0 Mil.

Australian Clinical Labs's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was A$40.0 Mil.

Australian Clinical Labs Issuance of Debt Related Terms

Australian Clinical Labs Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Australian Clinical Labs's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australian Clinical Labs Issuance of Debt Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23 Jun24 Jun25
Issuance of Debt
Get a 7-Day Free Trial 321.60 0.00 100.50 14.00 31.00

Australian Clinical Labs Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 14.00 0.00 26.00 5.00 35.00
ASX:ACL
56GF Score
Australian Clinical Labs Ltd ASX:ACL
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Australian Clinical Labs Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$40.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of A$40.0 Mil mean?
Australian Clinical Labs (ASX:ACL) has a Issuance of Debt of A$40.0 Mil as of Dec. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Australian Clinical Labs and its competitors.
Is Australian Clinical Labs' Issuance of Debt too high?
Australian Clinical Labs' current Issuance of Debt is A$40.0 Mil. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Issuance of Debt compare to TMO and DHR?
Australian Clinical Labs' Issuance of Debt of A$40.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Medical Diagnostics & Research company?
A good Issuance of Debt depends on the Medical Diagnostics & Research industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Australian Clinical Labs and its competitors. Australian Clinical Labs's current Issuance of Debt is A$40.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current Issuance of Debt is A$40.0 Mil. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Issuance of Debt is A$40.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?

Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued. The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06. GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.

Key valuation signals for ASX:ACL:

  • Issuance of Debt: A$40.0 Mil
  • GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Australian Clinical Labs Business Description

Address 1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score

Get the complete analysis for ASX:ACL

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.38
Price
A$3.06
GF Value